导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.51% | 2647/4773 |
| 近一周 | -2.15% | 1333/5462 |
| 近一月 | -4.02% | 2144/5421 |
| 近一季 | -7.15% | 2309/5209 |
| 近半年 | -2.47% | 1908/4920 |
| 近一年 | 0.84% | 2462/4366 |
| 近两年 | 43.09% | 1731/2954 |
| 近三年 | 25.24% | 1268/2253 |
| 成立以来 | 159.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.45% 3212/4961 |
12.09% 2235/5312 |
- - |
- - |
| 2025 | 18.68% 2292/4813 |
-1.22% 2612/3635 |
2.19% 1774/4076 |
17.45% 2499/4524 |
0.11% 2213/4813 |
| 2024 | 15.54% 915/3463 |
2.75% 714/2808 |
-1.17% 964/3014 |
15.88% 1605/3129 |
-1.81% 1838/3463 |
| 2023 | -9.59% 1196/2656 |
4.27% 1001/2280 |
-3.54% 822/2385 |
-3.43% 929/2515 |
-6.92% 1976/2655 |
| 2022 | -18.78% 755/2207 |
-13.73% 826/1919 |
6.69% 630/2016 |
-13.27% 870/2113 |
1.75% 1160/2208 |
| 2021 | 0.27% 719/1822 |
-2.31% 614/1255 |
5.56% 802/1330 |
-4.47% 710/1466 |
1.78% 802/1822 |
| 2020 | 38.48% 357/1250 |
-8.38% 603/1028 |
15.06% 518/1067 |
14.71% 265/1164 |
14.52% 269/1184 |
| 2019 | 39.32% 285/1092 |
26.77% 376/754 |
-0.13% 222/804 |
2.20% 316/850 |
7.67% 410/918 |
| 2018 | -22.48% 241/834 |
- - |
- - |
- - |
-12.57% 459/691 |
| 2017 | 24.64% 121/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.12% 193/605 |
- - |
- - |
- - |
- - |
| 2015 | 7.02% 183/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.87% 68/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.64% 101/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.38% 55/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.60% 62/102 |
- - |
- - |
- - |
- - |
| 2010 | -12.63% 36/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华沪深300ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |